US EditionNew leukemia drug offers hope for Iowa 4-year-old and others
IOWA, USA, JUL 20 – Blinatumomab lowers relapse rates in children with B-cell acute lymphoblastic leukemia from 10% to 4%, offering a less toxic alternative to traditional chemotherapy, doctors say.
- In Iowa, a new leukemia drug called blinatumomab is offering hope, and four-year-old Madi Seivert wore a flower backpack to carry her treatment.
- Last year, clinical trials for blinatumomab ended early due to clear benefits, and the drug is now standard practice, binding to leukemia cells to activate T-cells.
- Relapse rates demonstrate a decline from 10% to 4%, `97 percent will go on and not have to worry about having leukemia again`, Dr. Wendy Woods, Chief Medical Officer at Unity Point Health, said.
- Her hair and energy have returned during maintenance, and Ashley Seivert said `This is her survival` after seeing improvement.
- Families like the Seiverts are more hopeful than ever, and Dr. Wendy Woods anticipates blinatumomab will reshape childhood leukemia treatment over the next decade.
Insights by Ground AI
Does this summary seem wrong?
18 Articles
18 Articles
For many leukemia patients, a transplant of blood stem cells from donor bone marrow is the only way to recover. However, complications can arise: Graft-versus-host disease is one of them. Researchers at Friedrich-Alexander University...
Coverage Details
Total News Sources18
Leaning Left0Leaning Right0Center16Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
